Assessing the safety, impact and effectiveness of RTS,S/AS01E malaria vaccine following its introduction in three sub-Saharan African countries: methodological approaches and study set-up
Abstract Background Following a 30-year development process, RTS,S/AS01 E (GSK, Belgium) is the first malaria vaccine to reach Phase IV assessments. The World Health Organization-commissioned Malaria Vaccine Implementation Programme (MVIP) is coordinating the delivery of RTS,S/AS01 E through routine...
Saved in:
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
格式: | Artigo |
語言: | 英语 |
出版: |
2022
|
在線閱讀: | https://doi.org/10.1186/s12936-022-04144-3 https://malariajournal.biomedcentral.com/track/pdf/10.1186/s12936-022-04144-3 |
標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|